Welcome to ID4Pharma
Intelligent Drug Design Discovery Development (ID4Pharma/ID4)
Artificial Intelligent Drug R&D Platform
ID4 scientists have a solid expertise on R&D studies and established an Medicinal Chemistry/Biology Drug Discovery Platform integrated by "Big-data" machine/deep learning 'TargetHunter computing, bioassays, and medicinal chemistry knowledge.
Innovational Drug Discovery Patents
ID4 scientists' are the inventor(s) of multiple drug discovery patents consisting from terminal illness medications to augmented and virtual reality drug design platforms used for both commercial and educational functions.
Breakthrough Multiple Myeloma Treatment
Among the many patents that ID4Pharma owns, our patented sequestosome-1/p62-targeted small molecule Multiple Myeloma (MM) treatment has displayed a high anti-mm efficacy, toxicological safety, no drug resistance, and a good PK bio-availability superior to the markets' current treatment methods.
NIH Federal Fast Track Funding
ID4Pharma has received a $2.3 million NIH federal 'fast track' grant to carry out the FDA IND-enabling preclinical R&D studies in order to advance the discovered small molecule drug candidates to the next stage of experimental testing; ultimately achieving anti-MM clinical drug trials and marketability.
ID4Pharma has recently received a $2.3 Million NIH federal 'fast track' grant in order to advance the progression of our Multiple Myeloma drug to reach a new innovative treatment method.
What we are looking for
We are currently seeking strategic partnerships with pharma/biotech companies, investors and venture capitalists in order to achieve GLP-certifed data therefore allowing an FDA IND filing.